At Moffitt Cancer Center in Tampa, Florida, researchers have identified the molecular messenger that explains why uveal melanoma—the most common form of eye cancer—so often travels to the liver and takes hold there. The discovery, published in Cancer Research, zeroes in on a stress-response protein called GDF15, opening a path toward preventing or slowing one of the deadliest migrations cancer can take.
Uveal melanoma develops in the uvea, the middle layer of the eye that includes the iris. While it accounts for only about 5 percent of all melanomas, it carries an outsized threat: patients with high-risk class 2 tumors face a grim reality of liver metastasis, yet medicine currently has no FDA-approved way to prevent it. For decades, the puzzle has been why this cancer shows such a striking preference for the liver over other organs—a behavior that makes understanding the mechanism not merely academic but potentially lifesaving.
The research reveals an elegant, troubling choreography between cancer cells and the liver itself. When uveal melanoma cells reach the liver, they release unusually high levels of GDF15, a signaling protein that acts like a molecular ambassador. When liver stellate cells—support cells that normally repair tissue damage—encounter this GDF15, they respond by producing excessive collagen and fibronectin, the scaffolding molecules that form scar tissue. In healthy amounts, these materials support repair; in abundance, they create a permissive microenvironment where tumors can establish and thrive. The same interaction also triggers the growth of new blood vessels that feed the growing tumors with oxygen and nutrients, essentially building a tumor-supporting infrastructure.
But here's where hope enters the picture. When researchers experimentally blocked GDF15 in uveal melanoma cells, liver tumors became fewer and smaller. This single observation transforms GDF15 from a biological curiosity into a potential drug target with real clinical promise. Keiran Smalley, Ph.D., senior author and director of the Donald A. Adam Comprehensive Melanoma Research Center of Excellence at Moffitt, explains the implications: existing antibodies designed to treat cancer cachexia—a wasting condition caused by high GDF15—have proven highly effective in the lab and could potentially be repurposed as a therapy for uveal melanoma. Theoretically, early therapeutic targeting of GDF15 through such antibodies could delay or even prevent the outgrowth of liver metastases in high-risk patients.
The findings extend beyond eye cancer alone. GDF15 levels run abnormally high in colorectal, renal, lung, and bladder cancers. If the protein plays a similar role in enabling these cancers to spread, targeting GDF15 might offer a universal strategy for intercepting distant metastases across multiple cancer types—transforming what began as a study of one rare cancer into a platform for understanding and treating the spread of many.
Smalley's team has not yet answered why uveal melanoma shows such singular devotion to the liver, though evidence suggests cancer cells may spread to multiple organs but only truly flourish in the liver's soil. Regardless, the work represents a pivotal moment: the identification of a modifiable target that stands between diagnosis and the metastatic cascade that takes most lives. For patients with class 2 uveal melanoma, the possibility that GDF15 blockade could prevent or delay liver metastasis transforms an ancient death sentence into something medicine might finally begin to interrupt.